Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Gene therapy developer Voyager Therapeutics is angling for as much as $92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing debuts for life sciences companies. The company, a 2014 Fierce 15 honoree, is planning to offer about 4.7 million shares at between $15 and $17 each, setting aside another 703,125 shares for its underwriters to cover overalotments and trading under "VYGR" thereafter. Voyager's scheduled IPO comes amid an increasingly tough climate for biotech debutantes, as MyoKardia ($MYOK), Dimension Therapeutics ($DMTX), CytomX Therapeutics ($CTMX) and others have all priced at significant discounts over the past month. Voyager's lead program is a potential treatment for Parkinson's disease, and the company is working with Sanofi ($SNY) in a collaboration worth up to $845 million. More

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.